Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

Widespread HAIs Detected by Molecular Diagnostic Technique

By Labmedica International staff writers
Posted on 12 May 2014
A widespread healthcare infection is qualitatively detected using a molecular assay kit.

Qiagen NV (Venlo, The Netherlands), provider of sample and assay technologies, announced that its artus Clostridium difficile QS-RGQ MDX kit has been cleared by the US Food and Drug Administration (Silver Spring, MD, USA) for the qualitative detection of Clostridium difficile.

The FDA has also granted 510(k) regulatory clearance for the QIAsymphony RGQ MDx system, Qiagen's flagship automation platform that is transforming laboratory workflows and driving dissemination of molecular diagnostics.

The US milestone for Qiagen's global rollout of its sample-to-result automation platform, together with the FDA clearance of the first in a portfolio of tests for hospital acquired infections (HAIs), supports the expected growth in QIAsymphony placements globally to more than 1,250 by year-end 2014 and 1,500 by year-end 2015, the company said.

QIAsymphony RGQ MDx is a modular system for cost-effective handling of entire laboratory workflows. The three modules are QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup, and QIAGEN's real-time PCR detection platform Rotor-Gene Q MDx, which received FDA clearance in 2012.

The QIAsymphony family has the broadest test menu in its category in Europe and other markets. In the United States until now the system has been primarily used for laboratory-developed assays. The FDA clearance therefore marks an important milestone as a record number of assays are now positioned to be submitted for clearance or approval in the United States, a company representative said.

With the launch of the artus C. difficile test, QIAGEN now offers four FDA-regulated diagnostics designed to run on the QIAsymphony family of automated platforms. In Europe, more than 20 CE-marked assays run on the system. Innovation continues to expand the content menu, with about 35 new tests in development. The artus C. difficile kit, already available in Europe, will be the first US launch among Qiagen's advanced diagnostics for healthcare-associated infections.

Additional workflows for HAIs include the artus VanR QS-RGQ MDx Kit for detection of vancomycin-resistant bacteria, available in Europe and expected to be submitted in the second quarter 2014 to the FDA; the artus MRSA QS-RGQ MDx Kit for methicillin-resistant Staphylococcus aureus (MRSA), expected to be launched in Europe during the second quarter 2014 and to be submitted to the FDA in the third quarter 2014; and further other additions under development. QIAGEN also is in advanced stages of developing test kits for diagnosis of group B streptococcus and Herpes Simplex Virus (HSV1/2).

The artus C. difficile test was developed in partnership with IntelligentMDx under a multiyear agreement. IntelligentMDx (Cambridge, MA, USA) has entered into a multi-year development and license agreement with Qiagen (Venlo, The Netherlands) to design, develop, and manufacture several undisclosed CE-marked and FDA cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ automated platform. Financial terms have not been disclosed.

Related Links:

Qiagen
IntelligentMDx



EUROIMMUN AG
PURITAN MEDICAL
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image:  The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).

Noninvasive Method Captures Circulating Tumor Cells

A clinically proven, noninvasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing has been introduced. This noninvasive... Read more

Industry News

view channel

Beckman Coulter Acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business

Beckman Coulter (Brea, CA, USA), an indirect wholly-owned subsidiary of Danaher Corp. (Washington DC, MD, USA) has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (Chicago, IL, USA). The transaction is expected to close in the first quarter of 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.